Back to results
US 12,669,505 B2Granted
Detection of desmoglein-2 in cancers of epithelial origin
AssigneesHTD Bio Corp., University of Washington
InventorsDarrick Carter, Jiho Kim, Andre Lieber
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods of diagnosing, prognosing and stratifying cancers in a patient, comprising detecting elevated expression of desmoglein-2 (DSG-2) in a sample of the cancer and referencing that level to historic data to determine treatment regimen, stage, and prognosis of a patient.
Claims11
A method of treating a subject suffering from a chemo-resistant ovarian cancer, the method comprising:
- obtaining an ovarian cancer sample from the subject;
- detecting desmoglein-2 (DSG-2) expression in the ovarian cancer sample obtained from the subject;
- diagnosing the chemo-resistant ovarian cancer in the subject, wherein a higher amount of DSG-2 expression in the ovarian cancer sample following a treatment with one or more chemotherapeutic agents relative to DSG-2 expression in an ovarian cancer sample obtained from the subject prior to the treatment indicates that the ovarian cancer is chemo-resistant;
- administering to the subject an effective amount of a DSG-2 binding reagent, wherein the DSG-2 binding reagent comprises a junction opener;
- and
- administering the one or more chemotherapeutic agents.
3 more elements
Dependencies are inferred from the claim text.